Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C [Celivarone] 300 or 600mg for the conversion of atrial fibrillation/flutter.
Phase of Trial: Phase II
Latest Information Update: 07 May 2012
At a glance
- Drugs Celivarone (Primary)
- Indications Atrial fibrillation; Atrial flutter
- Focus Therapeutic Use
- Acronyms CORYFEE
- 22 Dec 2008 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
- 22 Dec 2008 Planned number of patients changed from 141 to 150 as reported by ClinicalTrials.gov.
- 05 Oct 2006 Status change